Literature DB >> 25451332

Angiotensin IV stimulates high atrial stretch-induced ANP secretion via insulin regulated aminopeptidase.

Byung Mun Park1, Seung Ah Cha1, Bo Ram Han1, Suhn Hee Kim2.   

Abstract

Angiotensin IV (Ang IV) is formed by aminopeptidase N (APN) from angiotensin III (Ang III) by removing the first N-terminal amino acid. Previously, we reported that angiotensin II (Ang II) inhibits atrial natriuretic peptide (ANP) secretion via angiotensin II type 1 receptor (AT1R). In contrast, angiotensin-(1-7) [Ang-(1-7)] and Ang III stimulate ANP secretion via Mas receptor (Mas R) and angiotensin II type 2 receptor (AT2R), respectively. However, it is not known whether there is any relationship between Ang IV and ANP secretion. Therefore, the aim of the present study was to determine the effect of Ang IV on ANP secretion and to find its downstream signaling pathway using in isolated perfused beating atria. Ang IV (0.1, 1 and 10μM) stimulated high atrial stretch-induced ANP secretion and ANP concentration in a dose-dependent manner. The augmented effect of Ang IV (1μM) on high atrial stretch-induced ANP secretion and concentration was attenuated by pretreatment with insulin-regulated aminopeptidase (IRAP) antagonist but not by AT1R or AT2R antagonist. Pretreatment with inhibitors of downstream signaling pathway including phosphatidylinositol 3-kinase (PI3K), protein kinase B (Akt) and mammalian target of rapamycin (mTOR) blocked Ang IV-induced ANP secretion and concentration. Therefore, these results suggest that Ang IV stimulates ANP secretion and concentration via IRAP and PI3K-Akt-mTOR pathway.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiotensin IV; Atrial natriuretic peptide; Heart; Insulin-regulated aminopeptidase; Signal pathway

Mesh:

Substances:

Year:  2014        PMID: 25451332     DOI: 10.1016/j.peptides.2014.10.016

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  5 in total

1.  Discovery of Selective Inhibitors of Endoplasmic Reticulum Aminopeptidase 1.

Authors:  Zachary Maben; Richa Arya; Digamber Rane; W Frank An; Shailesh Metkar; Marc Hickey; Samantha Bender; Akbar Ali; Tina T Nguyen; Irini Evnouchidou; Roger Schilling; Efstratios Stratikos; Jennifer Golden; Lawrence J Stern
Journal:  J Med Chem       Date:  2019-12-30       Impact factor: 7.446

Review 2.  Targeting Angiotensin-Converting Enzyme-2/Angiotensin-(1-7)/Mas Receptor Axis in the Vascular Progenitor Cells for Cardiovascular Diseases.

Authors:  Yagna P R Jarajapu
Journal:  Mol Pharmacol       Date:  2020-04-22       Impact factor: 4.436

3.  Plasma and tissue angiotensin-converting enzyme 2 activity and plasma equilibrium concentrations of angiotensin peptides in dogs with heart disease.

Authors:  Éva Larouche-Lebel; Kerry A Loughran; Mark A Oyama; Phil F Solter; Danielle S Laughlin; Melissa D Sánchez; Charles-Antoine Assenmacher; Philip R Fox; Ryan C Fries
Journal:  J Vet Intern Med       Date:  2019-06-28       Impact factor: 3.333

Review 4.  The renin-angiotensin-aldosterone system and its suppression.

Authors:  Marisa K Ames; Clarke E Atkins; Bertram Pitt
Journal:  J Vet Intern Med       Date:  2019-02-26       Impact factor: 3.333

5.  Effect of angiotensin receptor blockers and angiotensin converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in dogs with heart disease.

Authors:  Éva Larouche-Lebel; Kerry A Loughran; Terry Huh; Mark A Oyama
Journal:  J Vet Intern Med       Date:  2020-12-24       Impact factor: 3.175

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.